Piper Jaffray analyst Tyler Van Buren raised his price target for Ionis Pharmaceuticals (IONS) to $75 from $63 after the company and partner Roche (RHHBY) announced an update to the design of the ongoing Phase III study of IONIS-HTTRX in patients with Huntington's. More importantly, Ionis management stated that the OLE data "continue to look really good" and Roche maintains that it is planning to engage regulators later this year with respect to registration, Van Buren tells investors in a research note. The analyst views these statements as "particularly bullish" and added ~$4B in peak IONS-HTTRX revenues, or ~$600M in royalties, to his Ionis model. He keeps a Neutral rating on the shares.